Latest Breaking News On - ஜய்துச் ஆரோக்கியம் லிமிடெட் - Page 1 : comparemela.com

The earnings estimates are largely unchanged. It models revenue / EBITDA / PAT CAGR of 11% / 19% / 35% over FY21-23E – net profit likely to grow ahead of revenue and EBITDA driven by deleveraging of balance sheet. It maintains BUY with a DCF-based unchanged target price of Rs2,500. At the target price, the stock will trade at 35x P/E multiple Mar-23E. Key downside risks are delays or failures in new product development or inability to expand distribution. Promoter/FII Holdings Promoters held 64.8 per cent stake in the company as of June 30, 2021, while FIIs held 17 per cent, DIIs 10.7 per cent and public and others 7.5 per cent.

Zydus wellness ltdWellness ltdMid capஜய்துச் ஆரோக்கியம் லிமிடெட்ஆரோக்கியம் லிமிடெட்நடுவில் தொப்பி